[http://medical-dictionary.thefreedictionary.com/lymphoproliferative]Search in Google Scholar
[Primic Žakelj M, Bračko M, Hočevar M, Pompe-Kirn V, Strojan P, Zadnik V, Zakotnik B and Žagar T, editors. Cancer incidence in Slovenia 2006. Ljubljana: Institute of Oncology Ljubljana, Cancer registry of Republic of Slovenia; 2009.]Search in Google Scholar
[Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 2006; 66: 791-820.10.2165/00003495-200666060-0000516706552]Search in Google Scholar
[Molina A. A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma. Annu Rev Med 2008; 59: 237-50.10.1146/annurev.med.59.060906.22034518186705]Search in Google Scholar
[Zinzani PL, Pulsoni A, Perrotti A, Soverini S, Zaja F, De Renzo A, et al. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. J Clin Oncol 2004; 22: 2654-61.10.1200/JCO.2004.07.17015159414]Search in Google Scholar
[Nickenig C, D reyling M, Hoster E, Pfreundschuh M, Trumper L, Reiser M, et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: Results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006; 107: 1014-22.10.1002/cncr.2209316878325]Search in Google Scholar
[Sebban C, Mo unier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: The GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540 Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 1590-6.10.1200/JCO.2005.03.795216575010]Search in Google Scholar
[Hagenbeek A, Eghbali H, Monfardini S, Vitolo U, Hoskin PJ, de Wolf-Peeters C, et al. Phase III intergroup study of fludarabine phosphate compared with cyclophosphamide, vincristine, and prednisone chemotherapy in newly diagnosed patients with stage III and IV low-grade malignant non-Hodgkin's lymphoma. J Clin Oncol 2006; 24: 1590-6.10.1200/JCO.2005.03.7952]Search in Google Scholar
[Huic D, Mutvar A, Kinda-Basic S, Aurer I, Ciglar M, Grosev D, et al. Negative predictive value of F-18-FDG coincidence PET in patients with Hodgkin's disease and a residual mass after therapy: a retrospective diagnostic test study. Radiol Oncol 2009; 43: 258-63.10.2478/v10019-009-0024-x]Search in Google Scholar
[Bachy E, Brice P, Delarue R, Brousse N, Haioun C, Le Gouill S, et al. Longterm follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival - a study from the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2010; 28: 822-9.10.1200/JCO.2009.22.781920026809]Search in Google Scholar
[Samardziski M, Zafiroski G, Tolevska C, Kalicanin-Markovska M, Doncovska D, Anevska V, et al. Treatment of patients with "high grade" extremity localized chondrosarcoma. Preliminary results. Radiol Oncol 2009; 43: 187-94.]Search in Google Scholar
[Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am 2008; 46: 213-23.10.1016/j.rcl.2008.03.00318619377]Search in Google Scholar
[Salles G, Mounier N, de Guibert S, Morschhauser F, Doyen C, Rossi JF, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008; 112: 4824-31.10.1182/blood-2008-04-15318918799723]Search in Google Scholar
[Jezeršek Novaković B, Benigar A. Treatment of NonHodgkin's lymphomas with rituximab in Slovene patients. Med Oncol 2010; 27: 167-76.10.1007/s12032-009-9188-x]Search in Google Scholar
[Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003; 22: 7359-68.10.1038/sj.onc.1206939]Search in Google Scholar
[Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417-23.10.1182/blood-2004-08-3175]Search in Google Scholar
[Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725-32.10.1182/blood-2005-01-0016]Search in Google Scholar
[Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007; 25: 1986-92.10.1200/JCO.2006.06.4618]Search in Google Scholar
[Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-26.10.1200/JCO.2005.09.131]Search in Google Scholar
[Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-7.10.1200/JCO.2005.05.1003]Search in Google Scholar
[Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.10.1016/S1470-2045(06)70664-7]Search in Google Scholar